389 related articles for article (PubMed ID: 21233212)
1. KIBRA regulates Hippo signaling activity via interactions with large tumor suppressor kinases.
Xiao L; Chen Y; Ji M; Dong J
J Biol Chem; 2011 Mar; 286(10):7788-7796. PubMed ID: 21233212
[TBL] [Abstract][Full Text] [Related]
2. The Hippo pathway regulator KIBRA promotes podocyte injury by inhibiting YAP signaling and disrupting actin cytoskeletal dynamics.
Meliambro K; Wong JS; Ray J; Calizo RC; Towne S; Cole B; El Salem F; Gordon RE; Kaufman L; He JC; Azeloglu EU; Campbell KN
J Biol Chem; 2017 Dec; 292(51):21137-21148. PubMed ID: 28982981
[TBL] [Abstract][Full Text] [Related]
3. Angiomotins stimulate LATS kinase autophosphorylation and act as scaffolds that promote Hippo signaling.
Mana-Capelli S; McCollum D
J Biol Chem; 2018 Nov; 293(47):18230-18241. PubMed ID: 30266805
[TBL] [Abstract][Full Text] [Related]
4. Elevated expression of Par3 promotes prostate cancer metastasis by forming a Par3/aPKC/KIBRA complex and inactivating the hippo pathway.
Zhou PJ; Xue W; Peng J; Wang Y; Wei L; Yang Z; Zhu HH; Fang YX; Gao WQ
J Exp Clin Cancer Res; 2017 Oct; 36(1):139. PubMed ID: 29017577
[TBL] [Abstract][Full Text] [Related]
5. Deubiquitinating Enzyme USP9X Suppresses Tumor Growth via LATS Kinase and Core Components of the Hippo Pathway.
Toloczko A; Guo F; Yuen HF; Wen Q; Wood SA; Ong YS; Chan PY; Shaik AA; Gunaratne J; Dunne MJ; Hong W; Chan SW
Cancer Res; 2017 Sep; 77(18):4921-4933. PubMed ID: 28720576
[TBL] [Abstract][Full Text] [Related]
6. Tumor suppressor LATS1 is a negative regulator of oncogene YAP.
Hao Y; Chun A; Cheung K; Rashidi B; Yang X
J Biol Chem; 2008 Feb; 283(9):5496-509. PubMed ID: 18158288
[TBL] [Abstract][Full Text] [Related]
7. KIBRA regulates aurora kinase activity and is required for precise chromosome alignment during mitosis.
Zhang L; Iyer J; Chowdhury A; Ji M; Xiao L; Yang S; Chen Y; Tsai MY; Dong J
J Biol Chem; 2012 Oct; 287(41):34069-77. PubMed ID: 22904328
[TBL] [Abstract][Full Text] [Related]
8. Mst2 and Lats kinases regulate apoptotic function of Yes kinase-associated protein (YAP).
Oka T; Mazack V; Sudol M
J Biol Chem; 2008 Oct; 283(41):27534-27546. PubMed ID: 18640976
[TBL] [Abstract][Full Text] [Related]
9. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of Angiomotin by the LATS1/2 protein kinases.
Adler JJ; Johnson DE; Heller BL; Bringman LR; Ranahan WP; Conwell MD; Sun Y; Hudmon A; Wells CD
Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17368-73. PubMed ID: 24101513
[TBL] [Abstract][Full Text] [Related]
10. Evolutionary and molecular facts link the WWC protein family to Hippo signaling.
Wennmann DO; Schmitz J; Wehr MC; Krahn MP; Koschmal N; Gromnitza S; Schulze U; Weide T; Chekuri A; Skryabin BV; Gerke V; Pavenstädt H; Duning K; Kremerskothen J
Mol Biol Evol; 2014 Jul; 31(7):1710-23. PubMed ID: 24682284
[TBL] [Abstract][Full Text] [Related]
11. KIBRA protein phosphorylation is regulated by mitotic kinase aurora and protein phosphatase 1.
Xiao L; Chen Y; Ji M; Volle DJ; Lewis RE; Tsai MY; Dong J
J Biol Chem; 2011 Oct; 286(42):36304-15. PubMed ID: 21878642
[TBL] [Abstract][Full Text] [Related]
12. Role of Angiomotin-like 2 mono-ubiquitination on YAP inhibition.
Kim M; Kim M; Park SJ; Lee C; Lim DS
EMBO Rep; 2016 Jan; 17(1):64-78. PubMed ID: 26598551
[TBL] [Abstract][Full Text] [Related]
13. Angiomotin family proteins are novel activators of the LATS2 kinase tumor suppressor.
Paramasivam M; Sarkeshik A; Yates JR; Fernandes MJ; McCollum D
Mol Biol Cell; 2011 Oct; 22(19):3725-33. PubMed ID: 21832154
[TBL] [Abstract][Full Text] [Related]
14. WWC2 is an independent prognostic factor and prevents invasion via Hippo signalling in hepatocellular carcinoma.
Zhang Y; Yan S; Chen J; Gan C; Chen D; Li Y; Wen J; Kremerskothen J; Chen S; Zhang J; Cao Y
J Cell Mol Med; 2017 Dec; 21(12):3718-3729. PubMed ID: 28815883
[TBL] [Abstract][Full Text] [Related]
15. KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals.
Moleirinho S; Chang N; Sims AH; Tilston-Lünel AM; Angus L; Steele A; Boswell V; Barnett SC; Ormandy C; Faratian D; Gunn-Moore FJ; Reynolds PA
Oncogene; 2013 Apr; 32(14):1821-30. PubMed ID: 22614006
[TBL] [Abstract][Full Text] [Related]
16. The characterisation of LATS2 kinase regulation in Hippo-YAP signalling.
Hoa L; Kulaberoglu Y; Gundogdu R; Cook D; Mavis M; Gomez M; Gomez V; Hergovich A
Cell Signal; 2016 May; 28(5):488-497. PubMed ID: 26898830
[TBL] [Abstract][Full Text] [Related]
17. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway.
Chen M; Wang M; Xu S; Guo X; Jiang J
Oncotarget; 2015 Dec; 6(42):44466-79. PubMed ID: 26561204
[TBL] [Abstract][Full Text] [Related]
18. Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis.
Tanaka K; Osada H; Murakami-Tonami Y; Horio Y; Hida T; Sekido Y
Cancer Lett; 2017 Jan; 385():215-224. PubMed ID: 27773750
[TBL] [Abstract][Full Text] [Related]
19. Kibra is a regulator of the Salvador/Warts/Hippo signaling network.
Genevet A; Wehr MC; Brain R; Thompson BJ; Tapon N
Dev Cell; 2010 Feb; 18(2):300-8. PubMed ID: 20159599
[TBL] [Abstract][Full Text] [Related]
20. Ski regulates Hippo and TAZ signaling to suppress breast cancer progression.
Rashidian J; Le Scolan E; Ji X; Zhu Q; Mulvihill MM; Nomura D; Luo K
Sci Signal; 2015 Feb; 8(363):ra14. PubMed ID: 25670202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]